* Aronex Pharmaceuticals Inc., of The Woodlands, Texas, said it willexpand the clinical program for the HIV inhibitor, an oligonucleotidecalled AR177, to include a Phase I trial with multiple doses. Asingle-dose study is ongoing in HIV-positive patients.

* Cyanotech Corp., of Kailua-Kona, Hawaii, completed a publicoffering of 1.5 million shares at $7 each. Van Kasper & Co., of SanFrancisco, managed the offering.

* IMRE Corp., of Seattle, regained marketing rights to the Prosorbacolumn from Baxter Healthcare Corp., of Deerfield, Ill.

* Incyte Pharmaceuticals Inc., of Palo Alto, Calif., reached anagreement with GeneTrace Systems Inc., of Menlo Park, Calif., underwhich Incyte will license GeneTrace's mass spectrometry technologyand collaborate with the private company on development of specificDNA analysis applications. Incyte will make undisclosed milestonepayments, license fees and equity investments in GeneTrace.

* VIMRx Pharmaceuticals Inc., of Stamford, Conn., said a group ofinvestors led by Ronald Perelman, chairman of MacAndrews &Forbes Holdings Inc., agreed to buy $4.2 million in VIMRx equityconsisting of 2.8 million shares and 1.4 million warrants, eachexercisable for one share. In connection with the deal, DonaldDrapkin, a vice chairman at MacAndrews & Forbes, was electedVIMRx chairman.

(c) 1997 American Health Consultants. All rights reserved.